Proportion and clinical features of never-smokers with non-small cell lung cancer

Cho, Jaeyoung; Choi, Sun Mi; Lee, Jinwoo; Lee, Chang-Hoon; Lee, Sang-Min; Kim, Dong-Wan; Yim, Jae-Joon; Kim, Young Tae; Yoo, Chul-Gyu; Kim, Young Whan; Han, Sung Koo; Park, Young Sik

doi:10.1186/s40880-017-0187-6

Cancer Communications

Table 3 Multivariate analysis of overall survival using the Cox regression in 1860 patients with NSCLC

From: Proportion and clinical features of never-smokers with non-small cell lung cancer

Variable	Whole cohort (n = 1860)			Never-smokers (n = 707)			Ever-smokers (n = 1153)
Variable	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Smoking status				NA			NA
Ever-smoker	1.000
Never-smoker	0.624	0.460–0.848	0.003
Age^a	1.023	1.014–1.032	<0.001	1.005	0.988–1.021	0.582	1.029	1.018–1.040	<0.001
Sex
Male	1.000			1.000			1.000
Female	1.054	0.780–1.426	0.731	0.977	0.619–1.544	0.922	1.179	0.794–1.750	0.414
Histologic subtype
Adenocarcinoma	1.000			1.000			1.000
Squamous cell carcinoma	1.387	1.115–1.727	0.003	2.262	1.131–4.523	0.021	1.295	1.019–1.645	0.035
Others	1.506	1.184–1.915	0.001	1.066	0.618–1.839	0.818	1.586	1.201–2.095	0.001
ECOG PS
0–1	1.000			1.000			1.000
2–4	2.098	1.725–2.552	<0.001	2.743	1.732–4.343	<0.001	1.976	1.589–2.457	<0.001
Symptoms at diagnosis
Asymptomatic	1.000			1.000			1.000
Symptomatic	0.722	0.610–0.854	<0.001	0.715	0.503–1.015	0.061	0.737	0.608–0.894	0.002
EGFR mutations^b
Absent	1.000			1.000			1.000
Present	0.493	0.381–0.637	<0.001	0.516	0.352–0.757	0.001	0.459	0.314–0.671	<0.001
KRAS mutations^b
Absent	1.000			1.000			1.000
Present	1.560	1.085–2.243	0.017	2.540	1.253–5.150	0.010	1.416	0.921–2.176	0.113
ALK rearrangements^b
Absent	1.000			1.000			1.000
Present	0.397	0.239–0.660	<0.001	0.225	0.105–0.484	<0.001	0.723	0.362–1.444	0.358
Stage
I	1.000			1.000			1.000
II	2.087	1.387–3.143	<0.001	3.995	1.365–11.694	0.011	1.810	1.163–2.818	0.009
III	4.323	3.095–6.039	<0.001	4.470	1.872–10.671	0.001	4.036	2.797–5.824	<0.001
IV	10.314	7.507–14.172	<0.001	23.067	10.840–49.085	<0.001	8.437	5.908–12.049	<0.001
Treatment
Supportive/unknown	1.000			1.000			1.000
Antitumor	0.634	0.516–0.780	<0.001	0.377	0.214–0.662	0.001	0.678	0.541–0.849	0.001

NSCLC non-small cell lung cancer, HR hazard ratio, CI confidence interval, NA not applicable, ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, KRAS Kirsten rat sarcoma viral oncogene homolog, ALK anaplastic lymphoma kinase
^aAge was used as a continuous variable
^bThe individuals who did not undergo testing for each mutation were included in the multivariate analysis, however, the data are not shown

Back to article page

ISSN: 2523-3548

Contact us

General enquiries: info@biomedcentral.com